title: Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment.
abstract: OBJECTIVE
  To analyze histopathologic features related to myoma volume reduction after treatment with a GnRH agonist, buserelin acetate, in needle biopsy specimens obtained before treatment.
  
  
  METHODS
  Prospective clinical study.
  
  
  METHODS
  University teaching hospital.
  
  
  METHODS
  Twenty women with normal menstrual cycles and symptomatic uterine myomas.
  
  
  METHODS
  Buserelin acetate was administered intranasally (900 micrograms/d) for at least 16 weeks; transcervical needle biopsy of the uterine myoma was done before this treatment.
  
  
  METHODS
  The relation between histopathologic features (degree of cellularity, hyaline change, and collagen content) and the percent decrease in the volume of the largest myoma at 16 weeks measured by magnetic resonance imaging.
  
  
  RESULTS
  The correlation between the degree of hyaline change and the percent decrease in the myoma volume was significant, as was that with the proportion of collagenous tissue in the specimens.
  
  
  CONCLUSIONS
  We predicted myoma volume reduction after treatment with a GnRH agonist by histologic analysis of the uterine leiomyoma before treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka City University Medical School, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kawamura
authors.forename: F
authors.initials: F
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Ichimura
authors.forename: S
authors.initials: S
authors.lastname: Shibata
authors.forename: N
authors.initials: N
authors.lastname: Umesaki
authors.forename: S
authors.initials: S
authors.lastname: Ogita
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D002064:Buserelin